BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1275554)

  • 21. A comparative study of natural cytotoxicity and the leukocyte migration inhibition in human melanoma stages I and II.
    Kristensen E
    J Cancer Res Clin Oncol; 1980; 96(2):181-91. PubMed ID: 7391115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunology of malignant melanoma (author's transl)].
    Macher E; Sorg C; Seibert Er
    Langenbecks Arch Chir; 1976 Nov; 342():533-8. PubMed ID: 994670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demonstration of cellular immunity to tumor-specific antigens of malignant melanoma in hamsters by inhibition of macrophage migration.
    Henderson WR; Fukuyama K; Epstein WL; Spitler LE
    J Invest Dermatol; 1972 Apr; 58(4):229-32. PubMed ID: 5020976
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunology of melanoma].
    Vanwijck R; Bernheim JL; Lejeune FJ
    Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of leukocyte migration with melanoma-associated antigens in choroidal tumors.
    Char DH
    Invest Ophthalmol Vis Sci; 1977 Feb; 16(2):176-9. PubMed ID: 832980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of cellular immunity in melanoma by means of a modified leukocyte migration inhibition test].
    Bowszyc J; Bowszyc J; Wojnerowicz-Grajewska M; Milanowski L
    Przegl Dermatol; 1980; 67(3):319-23. PubMed ID: 6968922
    [No Abstract]   [Full Text] [Related]  

  • 27. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of leukocyte migration by soluble tumor extracts in human malignant melanoma.
    Lapińska M; Jassem J; Kondrat W; Jaśkiewicz J
    Neoplasma; 1980; 27(1):37-42. PubMed ID: 6154899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cellular immunity in patients with melanoma].
    Gorodinova VV; Kholenshed A; Babakova SV
    Vopr Onkol; 1976; 22(12):3-5. PubMed ID: 1020253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimelanoma immunity in vitiligo and melanoma patients.
    Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
    Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Delayed hypersensitivity reaction in malignant melanoma].
    Gorodilova VV; Saraeva ZM; Slesareva RI; Monzul' GD
    Vopr Onkol; 1973; 19(3):23-7. PubMed ID: 4762691
    [No Abstract]   [Full Text] [Related]  

  • 32. The NK function elucidated with respect to effector cells, target cells and other immunological in vitro tests.
    Kristensen E
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):449-53. PubMed ID: 6681340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Membrane associated antigens of human malignant melanoma. III. Specificity of human sera reacting with cultured melanoma cells.
    Seibert E; Sorg C; Happle R; Macher E
    Int J Cancer; 1977 Feb; 19(2):172-8. PubMed ID: 402317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An immunological aspect of melanoma and its potential application in adjuvant therapy.
    Elias EG; Tomazic VJ
    J Surg Oncol; 1991 Dec; 48(4):220-3. PubMed ID: 1745045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of human tumor-associated antigens by the leukocyte migration in agarose assay.
    Boddie AW; Urist MM; Chee DO; Holmes C; Morton DL
    Int J Cancer; 1976 Aug; 18(2):161-7. PubMed ID: 60286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma.
    Ernstoff MS; Duray P; Stenn K; Kirkwood JM
    J Invest Dermatol; 1985 May; 84(5):430-2. PubMed ID: 3889169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
    White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
    J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Identification of protein S 100 and melanoma-associated antigens in a comparative study of malignant melanoma and nevus pathology].
    Monti M; Berti E; Cavicchini S; Paindelli MG; Terragni L
    G Ital Dermatol Venereol; 1985; 120(4):297-306. PubMed ID: 3899920
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract]   [Full Text] [Related]  

  • 40. Cellular immunity to breast carcinoma and malignant melanoma.
    Cochran AJ; Mackie RM; Thomas CE; Grant RM; Cameron-Mowat DE; Spilg WG
    Br J Cancer Suppl; 1973 Aug; 1():77-82. PubMed ID: 4804293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.